Jincheng Pharm(SZ:300233) Xin Lang Cai Jing·2025-10-31 23:30Core Viewpoint - Jincheng Pharmaceutical is a leading enterprise in the domestic cephalosporin sector, with a comprehensive industry chain advantage, focusing on the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and finished formulations [1] Group 1: Business Performance - For Q3 2025, Jincheng Pharmaceutical reported revenue of 1.932 billion yuan, ranking 34th among 110 companies in the industry, while the industry leader, East China Pharmaceutical, achieved revenue of 32.664 billion yuan [2] - The net profit for the same period was 33.5981 million yuan, placing the company 67th in the industry, with the top performer, Hengrui Medicine, reporting a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Jincheng Pharmaceutical's debt-to-asset ratio was 27.69%, lower than the previous year's 32.87% and below the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 36.23%, down from 40.13% year-on-year and below the industry average of 57.17% [3] Group 3: Executive Compensation - The chairman, Zhao Yeqing, received a salary of 2.035 million yuan in 2024, an increase of 36,000 yuan from 2023 [4] - The president, Li Jiaquan, earned 1.833 million yuan in 2024, up by 34,000 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.49% to 25,800, while the average number of circulating A-shares held per shareholder increased by 9.27% to 14,400 [5] - Notable changes among the top ten circulating shareholders include the new entry of Fu Guo Precision Medical Flexible Allocation Mixed A, holding 4.961 million shares, and a reduction in holdings by Hong Kong Central Clearing Limited [5]